Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: BRN028
MIFTS: 74

Brain Cancer

Categories: Cancer diseases, Mental diseases, Neuronal diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Brain Cancer

About this section

MalaCards integrated aliases for Brain Cancer:

Name: Brain Cancer 12 55 15
Adult Brain Tumor 12 55 73
Neoplasm of Brain 12 29 6
Primary Malignant Neoplasm of Brain 12 73
Malignant Neoplasm of Brain 29 73
Brain Neoplasms 44 73
Brain Tumors 55 43
Malignant Primary Brain Neoplasm 12
Adult Malignant Brain Neoplasm 12
Malignant Tumor of Adult Brain 12
Malignant Primary Brain Tumors 55
Malignant Primary Brain Tumor 12
Malignant Tumor of Brain 12
Malignant Brain Tumour 12
Primary Brain Neoplasm 12
Brain Neoplasm, Adult 12
Brain Tumor, Primary 73
Primary Brain Tumor 12
Brain Tumor Primary 55
Tumor of the Brain 12
Brain Tumor, Adult 53
Bt - Brain Tumour 12
Brain Neoplasm 12
Cancer, Brain 40

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Neuronal diseases Mental diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:1319
ICD10 33 C71 C71.9
ICD9CM 35 191 191.9 239.6
MeSH 44 D001932
SNOMED-CT 68 93727008
Sources

Summaries for Brain Cancer

About this section
MedlinePlus : 43 A brain tumor is a growth of abnormal cells in the tissues of the brain. Brain tumors can be benign, with no cancer cells, or malignant, with cancer cells that grow quickly. Some are primary brain tumors, which start in the brain. Others are metastatic, and they start somewhere else in the body and move to the brain. Brain tumors can cause many symptoms. Some of the most common are Headaches, often in the morning Nausea and vomiting Changes in your ability to talk, hear, or see Problems with balance or walking Problems with thinking or memory Feeling weak or sleepy Changes in your mood or behavior Seizures Doctors diagnose brain tumors by doing a neurologic exam and tests including an MRI, CT scan, and biopsy. Treatment options include watchful waiting, surgery, radiation therapy, chemotherapy, and targeted therapy. Targeted therapy uses substances that attack cancer cells without harming normal cells. Many people get a combination of treatments. NIH: National Cancer Institute

MalaCards based summary : Brain Cancer, also known as adult brain tumor, is related to li-fraumeni syndrome and ganglioglioma, and has symptoms including seizures, tremor and back pain. An important gene associated with Brain Cancer is TP53 (Tumor Protein P53), and among its related pathways/superpathways are TGF-Beta Pathway and Cytokine Signaling in Immune system. The drugs Gliadel Wafer and Temodar have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and t cells, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Disease Ontology : 12 A central nervous system cancer that is characterized by the growth of abnormal cells in the tissues of the brain.

Wikipedia : 76 A brain tumor occurs when abnormal cells form within the brain. There are two main types of tumors:... more...

Sources

Related Diseases for Brain Cancer

About this section

Diseases related to Brain Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 504)
# Related Disease Score Top Affiliating Genes
1 li-fraumeni syndrome 32.7 EGFR IDH1 PTEN TP53
2 ganglioglioma 32.5 BRAF ENO2 GFAP NES SMARCB1 TP53
3 central neurocytoma 32.3 ENO2 GFAP NES
4 subependymoma 32.0 ENO2 GFAP NES
5 gliomatosis cerebri 31.8 EGFR GFAP IDH1 NES PTEN TP53
6 subependymal giant cell astrocytoma 31.8 ENO2 GFAP NES
7 supratentorial cancer 31.8 AKT1 EGFR GFAP IDH1 IDH2 MGMT
8 brain glioma 31.7 EGFR GFAP IDH1 MGMT NES TP53
9 cerebral neuroblastoma 31.7 ENO2 GFAP TP53
10 infratentorial cancer 31.7 NES SMARCB1 TP53
11 atypical teratoid rhabdoid tumor 31.6 GFAP SMARCB1 TP53
12 anaplastic ganglioglioma 31.6 GFAP NES
13 rhabdoid cancer 31.0 ENO2 SMARCB1 TP53
14 gliosarcoma 30.8 EGFR ENO2 GFAP IDH1 MGMT NES
15 glioblastoma 30.7 AKT1 ALK BRAF EGFR IDH1 IDH2
16 gemistocytic astrocytoma 30.6 GFAP IDH2 PTEN
17 glioma susceptibility 1 30.6 GFAP IDH1 IDH2 TP53
18 cerebral ventricle cancer 30.6 ENO2 GFAP SMARCB1 TP53
19 astroblastoma 30.6 ENO2 GFAP NES
20 oligoastrocytoma 30.6 GFAP IDH2 MGMT
21 protoplasmic astrocytoma 30.6 GFAP IDH2 TP53
22 glioma 30.6 BRAF EGFR IDH1 IDH2 MIR25 PIK3CA
23 grade iii astrocytoma 30.6 EGFR GFAP IDH2 MGMT PTEN TP53
24 fibrillary astrocytoma 30.6 GFAP IDH1 IDH2 MGMT TP53
25 glioblastoma multiforme 30.6 AKT1 EGFR GFAP IDH1 MGMT NES
26 ependymoblastoma 30.6 GFAP NES TP53
27 ewing sarcoma 30.6 AKT1 ALK BMI1 EGFR ENO2 GFAP
28 pilocytic astrocytoma 30.6 BRAF GFAP IDH1
29 ependymoma 30.6 EGFR ENO2 GFAP MGMT NES
30 pleomorphic xanthoastrocytoma 30.5 BRAF GFAP IDH1 MGMT SMARCB1 TP53
31 small cell cancer of the lung 30.4 AKT1 EGFR ENO2 PIK3CA PTEN TP53
32 hydrocephalus 30.4 ENO2 GFAP NES PTEN TP53
33 adenocarcinoma 30.3 AKT1 ALK BRAF EGFR PIK3CA PTEN
34 juvenile pilocytic astrocytoma 30.3 ENO2 GFAP TP53
35 stroke, ischemic 30.2 AKT1 ENO2 NES PIK3CA
36 neuroma 30.2 ENO2 GFAP SMARCB1
37 meningioma, familial 30.2 AKT1 ENO2 GFAP PTEN SMARCB1 TP53
38 squamous cell carcinoma, head and neck 30.1 AKT1 BRAF EGFR IDH2 PIK3CA PTEN
39 squamous cell carcinoma 30.1 AKT1 BRAF EGFR PIK3CA PTEN TP53
40 gastric cancer 30.1 AKT1 DANCR EGFR MGMT MIR25 PIK3CA
41 giant cell glioblastoma 30.1 BRAF EGFR GFAP IDH1 MGMT PTEN
42 erdheim-chester disease 30.1 BRAF NRAS PIK3CA
43 lung cancer 30.0 AKT1 ALK BRAF DANCR EGFR ENO2
44 colorectal cancer 30.0 AKT1 BRAF DANCR EGFR EPHB2 MGMT
45 central nervous system cancer 30.0 AKT1 EGFR ENO2 GFAP IDH1 IDH2
46 anaplastic oligodendroglioma 30.0 EGFR GFAP IDH2 MGMT
47 nervous system cancer 30.0 AKT1 EGFR ENO2 GFAP IDH1 MGMT
48 oligodendroglioma 30.0 EGFR ENO2 GFAP IDH1 IDH2 MGMT
49 small cell carcinoma 30.0 EGFR ENO2 PTEN TP53
50 breast adenocarcinoma 29.9 AKT1 EGFR PIK3CA PTEN TP53

Comorbidity relations with Brain Cancer via Phenotypic Disease Network (PDN):


Acute Cystitis Brain Edema
Epilepsy, Focal, with Speech Disorder and with or Without Mental Retardation Hypertension, Essential
Obstructive Hydrocephalus Schizophreniform Disorder

Graphical network of the top 20 diseases related to Brain Cancer:



Diseases related to Brain Cancer
Sources

Symptoms & Phenotypes for Brain Cancer

About this section

UMLS symptoms related to Brain Cancer:


seizures, tremor, back pain, pain, headache, syncope, chronic pain, sciatica, vertigo/dizziness, sleeplessness

GenomeRNAi Phenotypes related to Brain Cancer according to GeneCards Suite gene sharing:

26 (show top 50) (show all 63)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.7 NES
2 Increased shRNA abundance (Z-score > 2) GR00366-A-110 10.7 BRAF
3 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.7 BMI1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.7 EGFR PTPN11
5 Increased shRNA abundance (Z-score > 2) GR00366-A-12 10.7 TP53
6 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.7 TP53
7 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.7 EGFR PTPN11
8 Increased shRNA abundance (Z-score > 2) GR00366-A-123 10.7 NES
9 Increased shRNA abundance (Z-score > 2) GR00366-A-132 10.7 TP53
10 Increased shRNA abundance (Z-score > 2) GR00366-A-138 10.7 PTPN11
11 Increased shRNA abundance (Z-score > 2) GR00366-A-147 10.7 NES
12 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.7 BRAF PTPN11
13 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.7 PTEN
14 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.7 PTEN
15 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.7 PIK3CA
16 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.7 AKT1 IDH2 PIK3CA NES PTEN
17 Increased shRNA abundance (Z-score > 2) GR00366-A-166 10.7 BRAF PIK3CA
18 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.7 PTEN
19 Increased shRNA abundance (Z-score > 2) GR00366-A-169 10.7 TP53
20 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.7 IDH2
21 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.7 AKT1 BMI1 BRAF IDH2 PIK3CA
22 Increased shRNA abundance (Z-score > 2) GR00366-A-178 10.7 PTPN11
23 Increased shRNA abundance (Z-score > 2) GR00366-A-186 10.7 NES
24 Increased shRNA abundance (Z-score > 2) GR00366-A-19 10.7 TP53
25 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.7 BMI1 PIK3CA EGFR PTPN11 TP53
26 Increased shRNA abundance (Z-score > 2) GR00366-A-194 10.7 BRAF
27 Increased shRNA abundance (Z-score > 2) GR00366-A-196 10.7 NES
28 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.7 IDH2
29 Increased shRNA abundance (Z-score > 2) GR00366-A-205 10.7 NES
30 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.7 EGFR
31 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.7 PTEN EGFR
32 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.7 BRAF
33 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.7 BMI1
34 Increased shRNA abundance (Z-score > 2) GR00366-A-31 10.7 BRAF
35 Increased shRNA abundance (Z-score > 2) GR00366-A-32 10.7 BRAF
36 Increased shRNA abundance (Z-score > 2) GR00366-A-35 10.7 TP53
37 Increased shRNA abundance (Z-score > 2) GR00366-A-37 10.7 PTPN11
38 Increased shRNA abundance (Z-score > 2) GR00366-A-39 10.7 TP53
39 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.7 AKT1 IDH2 PIK3CA PTEN
40 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.7 EGFR
41 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.7 BRAF PTPN11
42 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.7 PIK3CA
43 Increased shRNA abundance (Z-score > 2) GR00366-A-50 10.7 AKT1
44 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.7 BMI1 PTEN
45 Increased shRNA abundance (Z-score > 2) GR00366-A-69 10.7 IDH2
46 Increased shRNA abundance (Z-score > 2) GR00366-A-7 10.7 PTPN11
47 Increased shRNA abundance (Z-score > 2) GR00366-A-70 10.7 AKT1
48 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.7 IDH2
49 Increased shRNA abundance (Z-score > 2) GR00366-A-78 10.7 PTPN11
50 Increased shRNA abundance (Z-score > 2) GR00366-A-79 10.7 AKT1

MGI Mouse Phenotypes related to Brain Cancer:

46 (show all 22)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.38 AKT1 ALK BRAF ENO2 EPHB2 GFAP
2 growth/size/body region MP:0005378 10.38 AKT1 ALK BRAF EGFR ENO2 EPHB2
3 cellular MP:0005384 10.36 AKT1 BRAF EGFR ENO2 EPHB2 GFAP
4 homeostasis/metabolism MP:0005376 10.34 AKT1 ALK BRAF EGFR GFAP IDH1
5 cardiovascular system MP:0005385 10.33 AKT1 BRAF EGFR GFAP IDH2 NRAS
6 mortality/aging MP:0010768 10.3 AKT1 ALK BRAF EGFR EPHB2 GFAP
7 endocrine/exocrine gland MP:0005379 10.29 AKT1 ALK BRAF EGFR EPHB2 MGMT
8 immune system MP:0005387 10.25 AKT1 BRAF EGFR GFAP IDH1 NRAS
9 digestive/alimentary MP:0005381 10.22 BRAF EGFR EPHB2 GFAP NRAS PTEN
10 embryo MP:0005380 10.21 AKT1 BRAF EGFR NRAS PIK3CA PTEN
11 neoplasm MP:0002006 10.18 AKT1 ALK BRAF EGFR IDH2 MGMT
12 adipose tissue MP:0005375 10.15 AKT1 BRAF EGFR PIK3CA PTEN PTPN11
13 integument MP:0010771 10.15 AKT1 ALK BRAF EGFR NRAS PIK3CA
14 nervous system MP:0003631 10.15 AKT1 ALK BRAF EGFR ENO2 EPHB2
15 craniofacial MP:0005382 10.12 BRAF EGFR ENO2 EPHB2 NRAS PTPN11
16 muscle MP:0005369 10.09 AKT1 BRAF EGFR GFAP PIK3CA PTEN
17 liver/biliary system MP:0005370 10.08 AKT1 BRAF EGFR NRAS PTEN PTPN11
18 reproductive system MP:0005389 9.96 AKT1 ALK BRAF EGFR EPHB2 PIK3CA
19 pigmentation MP:0001186 9.87 ALK BRAF EGFR NRAS PTEN PTPN11
20 respiratory system MP:0005388 9.85 AKT1 ALK BRAF EGFR ENO2 IDH1
21 skeleton MP:0005390 9.65 AKT1 ALK BRAF EGFR IDH1 NRAS
22 vision/eye MP:0005391 9.36 ALK BRAF EGFR EPHB2 GFAP NRAS
Sources

Drugs & Therapeutics for Brain Cancer

About this section

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Gliadel Wafer 18 49 CARMUSTINE Rhone-Poulenc Rorer, Guilford Pharmaceuticals February 1997
2
Temodar 18 49 TEMOZOLOMIDE Schering-Plough August 1999
3
Alecensa 18 ALECTINIB HYDROCHLORIDE Roche December 2015

Drugs for Brain Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 747)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
2
Morphine Approved, Investigational Phase 4,Phase 2 57-27-2 5288826
3
Hydrocortisone Approved, Vet_approved Phase 4,Not Applicable 50-23-7 5754
4
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3,Not Applicable 113775-47-6 68602 5311068
5
Hydrocortisone acetate Approved, Vet_approved Phase 4,Not Applicable 50-03-3
6
Prednisone Approved, Vet_approved Phase 4,Phase 2 53-03-2 5865
7
Sevoflurane Approved, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 28523-86-6 5206
8
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 437-38-7 3345
9
Temozolomide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 85622-93-1 5394
10
Dacarbazine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 4342-03-4 5351166
11
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
12
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 2078-54-8 4943
13
Midazolam Approved, Illicit Phase 4,Not Applicable 59467-70-8 4192
14
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 58-05-9 6006 143
15
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2 83-43-2 6741
16
Prednisolone Approved, Vet_approved Phase 4,Phase 2 50-24-8 5755
17
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 2 302-25-0
18
Methylprednisolone hemisuccinate Approved Phase 4,Phase 2 2921-57-5
19
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 94-09-7, 1994-09-7 2337
20 tannic acid Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
21 Piracetam Approved, Investigational Phase 4,Phase 2 7491-74-9
22
Clevidipine Approved, Investigational Phase 4 167221-71-8
23
Labetalol Approved Phase 4 36894-69-6 3869
24
Hydralazine Approved Phase 4 86-54-4 3637
25
Methylphenidate Approved, Investigational Phase 4,Phase 3,Not Applicable 113-45-1 4158
26
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-61-6, 62-31-7 681
27
Thrombin Approved, Investigational Phase 4
28
Bupivacaine Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 2180-92-9, 38396-39-3 2474
29
Rocuronium Approved Phase 4,Not Applicable 119302-91-9, 143558-00-3 441290
30
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
31
Phenylephrine Approved Phase 4 59-42-7 6041
32
Pseudoephedrine Approved Phase 4 90-82-4 7028
33
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
34
Ephedrine Approved Phase 4 299-42-3 9294
35
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 7487-88-9 24083
36
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
37
Propranolol Approved, Investigational Phase 4 525-66-6 4946
38
Cabergoline Approved Phase 4,Phase 3,Phase 2,Not Applicable 81409-90-7 54746
39
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83150-76-9 383414 6400441
40
Somatostatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 51110-01-1, 38916-34-6 53481605
41
Warfarin Approved Phase 4 81-81-2 6691 54678486
42
Apixaban Approved Phase 4,Phase 3 503612-47-3 10182969
43
Heparin Approved, Investigational Phase 4,Phase 3,Not Applicable 9005-49-6 772 46507594
44
Phytonadione Approved, Investigational Phase 4,Phase 1 84-80-0 4812 5284607
45
Remifentanil Approved Phase 4,Phase 3,Not Applicable 132875-61-7 60815
46
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
47
Ibuprofen Approved Phase 4,Phase 3 15687-27-1 3672
48
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
49
Acetaminophen Approved Phase 4,Phase 2 103-90-2 1983
50
Trimethoprim Approved, Vet_approved Phase 4,Phase 1 738-70-5 5578

Interventional clinical trials:

(show top 50) (show all 2091)
# Name Status NCT ID Phase Drugs
1 Single Dose Tramadol Effect on Extubation Response and Quality of Emergence Post-supratentorial Intracranial Surgery Unknown status NCT02964416 Phase 4 Injection Tramadol
2 Comparison of Efficacy and Safety of the Postoperative Analgesia Methods Unknown status NCT02929147 Phase 4 Morphine;Dexketoprofen;Placebo
3 Effect of Dexmedetomidine on Plasmatic Cortisol Response in Transsphenoidal Surgery Unknown status NCT02549768 Phase 4 Dexmedetomidine;Sodium Chloride 0.9%
4 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4 Hydrocortisone;Prednisone
5 Trial of Levetiracetam in Patients With Primary Brain Tumors and Symptomatic Seizures Who Undergo Surgery Completed NCT00571155 Phase 4 levetiracetam
6 Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors Completed NCT02034708 Phase 4 Dotarem®;Gadovist®/Gadavist®
7 Perampanel in Seizure Patients With Primary Glial Brain Tumors Completed NCT02363933 Phase 4 Perampanel
8 Surgery Versus Radiosurgery to Treat Metastatic Brain Tumors Completed NCT00075166 Phase 4
9 A Pilot Study to Evaluate Efficacy and Safety of Clevidipine in Neurosurgical Patients Completed NCT00952081 Phase 4 Clevidipine
10 Multihance at 3 Tesla in Brain Tumors Completed NCT00395863 Phase 4 Multihance;Arm 2 - Magnevist
11 Learning Impairments Among Survivors of Childhood Cancer Completed NCT00576472 Phase 4 Methylphenidate
12 Phase IV Bioseal Study in Brain Tumor Surgery Completed NCT02034799 Phase 4
13 Scalp Nerve Block and Opioid Consumption in Brain Surgery Completed NCT02057367 Phase 4 Scalp block with 0.5% plain Marcaine;Scalp block with 0.9% normal saline
14 Sugammadex Given for the Reversal of Rocuronium Induced Neuromuscular Blockade Under Sevoflurane Anesthesia in Infants Completed NCT02708056 Phase 4 Sugammadex
15 The Use of Fentanyl in General Anesthesia for Craniotomy With or Without 0.5% Levobupivacaine Scalp Block Completed NCT02558569 Phase 4 Levobupivacaine
16 Bioequivalence Study of Temozolomide in Patients With Primary Tumors of the Central Nervous System Completed NCT02343081 Phase 4 Temozolomide;Temozolomide
17 Vasopressor Effects in Anesthetized Patients Completed NCT02713087 Phase 4 Ephedrine;Phenylephrine
18 Dexmedetomidine and Intelligence Development in Pediatric Patients Undergoing Craniotomy Completed NCT02810899 Phase 4 dexmedetomidine;normal saline
19 Magnesium Sulphate for Attenuation of Hemodynamic Pressor Response After Myfield's Clamp Application Completed NCT03318471 Phase 4 MgSo4;0.9% NaCl
20 Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation Completed NCT00336531 Phase 4 itraconazole
21 Crossover Comparison of MultiHance and Dotarem Completed NCT02070380 Phase 4 MultiHance 0.1 mmol/kg;Dotarem;MultiHance 0.05 mmol/kg
22 Comparison of Prohance® With Gadovist®/Gadavistâ„¢ in Magnetic Resonance Imaging (MRI) of the Brain Completed NCT01613417 Phase 4 gadoteridol;gadobutrol
23 A Study Comparing Two Magnetic Resonance Imaging (MRI) Contrast Agents in MRI of the Brain Completed NCT00323102 Phase 4 Multihance
24 Using Propranolol in Traumatic Brain Injury to Reduce Sympathetic Storm Phenomenon Completed NCT03401515 Phase 4 Propranolol Hydrochloride 1 MG/ML
25 Validation of 3 Dimensional Laparoscopic System in Disral Pancreatectomy and Splenectomy Completed NCT02757690 Phase 4
26 Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly Completed NCT00376064 Phase 4 Octreotide acetate and cabergoline/Octrotide and Somavert
27 Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion) Completed NCT02100228 Phase 4 Apixaban;Parenteral heparin and/or oral Vitamin K antagonist
28 Remifentanil Infusion Alone During the Closure Period for Early Emergence Following Craniotomy Completed NCT02593942 Phase 4 Remifentanil;Propofol
29 Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors Completed NCT02351700 Phase 4 IV Caldolor (IV Ibuprofen);IV Ibuprofen placebo
30 Surgical Debulking of Pituitary Adenomas Completed NCT01371643 Phase 4 Octreotide LAR
31 Light Sedation or Intubated General Anesthesia in Patients With Brain Cancer Undergoing Craniotomy Recruiting NCT02193568 Phase 4
32 1 Week Versus 6 Weeks of Levetiracetam in Surgical Brain Tumor Patients Recruiting NCT02334722 Phase 4 Levetiracetam extended release
33 Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions Recruiting NCT02478346 Phase 4 Fluorescein Sodium
34 Comparative Low and High Dose of Dexmedethomidine in Pituitary Tumor Removal by Transphenoid Approach Recruiting NCT03132259 Phase 4 high dose dexmedethomidine;low dose dexmedethomidine
35 Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions Recruiting NCT03014687 Phase 4 Placebo;Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole
36 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4 Pasireotide
37 Quality Improvement and Practice Based Research in Neurology Using the EMR Enrolling by invitation NCT02670161 Phase 4 Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)
38 Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in NSCLC Not yet recruiting NCT03799601 Phase 4 Anlotinib;Docetaxel;Carboplatin
39 Treatment of Resectable Malignant Brain Tumors Terminated NCT00415467 Phase 4
40 Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions Terminated NCT02028325 Phase 4 Fluorescein Sodium
41 Use of Conivaptan (Vaprisol) for Hyponatremic Neuro-ICU Patients Terminated NCT00727090 Phase 4 Conivaptan
42 A Pilot Study of Pre- and Post-operative Use of Somatuline Depot. Terminated NCT01861717 Phase 4 lanreotide
43 Post-approval Study of NovoTTF-100A in Recurrent GBM Patients Terminated NCT01756729 Phase 4
44 Genetically-informed Therapies for Patients With Metastatic Cancer Withdrawn NCT02000739 Phase 4
45 3D Ultra Sound for Resection of Brain Tumors Unknown status NCT02150564 Phase 3
46 Efficacy of Tranexamic Acid in Brain Tumor Resections Unknown status NCT01655927 Phase 3 Tranexamic Acid;Placebo: Saline
47 Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer Unknown status NCT00045968 Phase 3 Dendritic cell immunotherapy
48 SCRT Versus Conventional RT in Children and Young Adults With Low Grade and Benign Brain Tumors Unknown status NCT00517959 Phase 3
49 Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
50 Local Radiotherapy Following Complete Resection of a Brain Metastasis Unknown status NCT02729558 Phase 3

Search NIH Clinical Center for Brain Cancer

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: brain neoplasms

Sources

Genetic Tests for Brain Cancer

About this section

Genetic tests related to Brain Cancer:

# Genetic test Affiliating Genes
1 Neoplasm of Brain 29
2 Malignant Neoplasm of Brain 29
Sources

Anatomical Context for Brain Cancer

About this section

MalaCards organs/tissues related to Brain Cancer:

41
Brain, Testes, T Cells, Lung, Prostate, Liver, Bone
Sources

Publications for Brain Cancer

About this section

Articles related to Brain Cancer:

(show top 50) (show all 638)
# Title Authors Year
1
Analyses of temporal and spatial patterns of glioblastoma multiforme and other brain cancer subtypes in relation to mobile phones using synthetic counterfactuals. ( 30384227 )
2019
2
Perilesional edema in brain cancer: Independent prognosticator or epiphenomenon of biomolecular signature? ( 29331541 )
2018
3
Epstein-Barr virus- and cytomegalovirus-specific immune response in patients with brain cancer. ( 29970101 )
2018
4
A Repurposed Drug for Brain Cancer: Enhanced Atovaquone Amorphous Solid Dispersion by Combining a Spontaneously Emulsifying Component with a Polymer Carrier. ( 29783757 )
2018
5
Does Risk of Brain Cancer Increase with Intracranial Volume? A Population-Based Case-Control Study. ( 29554311 )
2018
6
Vascular targeting of LIGHT normalizes blood vessels in primary brain cancer and induces intratumoural high endothelial venules. ( 29603739 )
2018
7
Brain Cancer: Implication to Disease, Therapeutic Strategies and Tumor Targeted Drug Delivery Approaches. ( 29189177 )
2018
8
Brain-Resident Microglia and Blood-Borne Macrophages Orchestrate Central Nervous System Inflammation in Neurodegenerative Disorders and Brain Cancer. ( 29681904 )
2018
9
Spatio-spectral classification of hyperspectral images for brain cancer detection during surgical operations. ( 29554126 )
2018
10
Response to 'Perilesional edema in brain cancer: Independent prognosticator or epiphenomenon of biomolecular signature?' ( 29343408 )
2018
11
Heart Variability Biofeedback as Supplementary Care for Brain Cancer: A Feasibility Study. ( 29653058 )
2018
12
Development of core-shell nanocarrier system for augmenting piperine cytotoxic activity against human brain cancer cell line. ( 29597041 )
2018
13
Micro-imaging of Brain Cancer Radiation Therapy Using Phase-contrast Computed Tomography. ( 29976510 )
2018
14
Biofabrication of morphology improved cadmium sulfide nanoparticles using Shewanella oneidensis bacterial cells and ionic liquid: For toxicity against brain cancer cell lines. ( 29207279 )
2018
15
The role of income in brain tumor patients: a descriptive register-based study : No correlation between patients' income and development of brain cancer. ( 29532282 )
2018
16
Special Issue on Precision Medicine for Brain Cancer in ACS Chemical Neuroscience. ( 29338188 )
2018
17
Validation of the Chinese version of EORTC QLQ-BN20 for patients with brain cancer. ( 29461664 )
2018
18
Investigating the Ketogenic Diet As Treatment for Primary Aggressive Brain Cancer: Challenges and Lessons Learned. ( 29536011 )
2018
19
The biochemical, nanomechanical and chemometric signatures of brain cancer. ( 28688336 )
2018
20
Patients' experiences and care needs during the diagnostic phase of an integrated brain cancer pathway: A case study. ( 29603812 )
2018
21
Brain cancer genomics and epigenomics. ( 29478614 )
2018
22
Melatonin disturbs SUMOylation-mediated crosstalk between c-Myc and nestin via MT1 activation and promotes the sensitivity of paclitaxel in brain cancer stem cells. ( 29654697 )
2018
23
Curcumin-lipoic acid conjugate as a promising anticancer agent on the surface of golda89iron oxide nanocomposites: A pH-sensitive targeted drug delivery system for brain cancer theranostics. ( 29248558 )
2018
24
Enhanced Photogeneration of Reactive Oxygen Species and Targeted Photothermal Therapy of C6 Glioma Brain Cancer Cells by Folate-Conjugated Gold-Photoactive Polymer Nanoparticles. ( 29787247 )
2018
25
Primary and metastatic brain cancer genomics and emerging biomarkers for immunomodulatory cancer treatment. ( 29391205 )
2018
26
Brain Cancer Imaging Phenomics Toolkit (brain-CaPTk): An Interactive Platform for Quantitative Analysis of Glioblastoma. ( 29733087 )
2018
27
The Molecular Mechanisms of Plant-Derived Compounds Targeting Brain Cancer. ( 29385679 )
2018
28
Correction: SlicerDMRI: Open Source Diffusion MRI Software for Brain Cancer Research. ( 29716952 )
2018
29
Could a plant derived protein potentiate the anticancer effects of a stem cell in brain cancer? ( 29765540 )
2018
30
Inhibition of Translesion DNA Synthesis as a Novel Therapeutic Strategy to Treat Brain Cancer. ( 29259011 )
2018
31
Nanotheranostics: Emerging Strategies for Early Diagnosis and Therapy of Brain Cancer. ( 29291164 )
2018
32
Adolescent and Young Adult Brain Tumor Survivors Report Increased Anxiety Even Years After Successful Treatment for Relapse. ( 30156441 )
2018
33
Brain cancer. ( 30258154 )
2018
34
Immunotherapy offers a promising bet against brain cancer. ( 30258155 )
2018
35
Breaking down the epidemiology of brain cancer. ( 30258156 )
2018
36
How cerebral organoids are guiding brain-cancer research and therapies. ( 30258158 )
2018
37
See brain cancer as more than just the sum of biology. ( 30258159 )
2018
38
The unexpected role of histones in childhood brain cancer. ( 30258160 )
2018
39
The genomics of brain cancer. ( 30258161 )
2018
40
Improving brain-cancer therapies through mathematical modelling. ( 30258162 )
2018
41
Searching for the roots of brain cancer. ( 30258163 )
2018
42
The innovative therapies that could break the brain-cancer stalemate. ( 30258164 )
2018
43
Prospective memory impairment following whole brain radiotherapy in patients with metastatic brain cancer. ( 30259694 )
2018
44
Serially measured pre-diagnostic levels of serum cytokines and risk of brain cancer in active component military personnel. ( 30297770 )
2018
45
The Multiple Roles of Peptidyl Prolyl Isomerases in Brain Cancer. ( 30314361 )
2018
46
Drug Screening of Human GBM Spheroids in Brain Cancer Chip. ( 30337660 )
2018
47
Holistic needs assessment in brain cancer patients: A systematic review of available tools. ( 30362194 )
2018
48
Translation of Carbon-13 EPI for hyperpolarized MR molecular imaging of prostate and brain cancer patients. ( 30375043 )
2018
49
Molecular Mechanisms Governing the Stem Cell's Fate in Brain Cancer: Factors of Stemness and Quiescence. ( 30510501 )
2018
50
Glycosylation Changes in Brain Cancer. ( 28982002 )
2018